Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | QPCT | Q16769 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4398713 | 0.98 | POLB (0.58) | POLBALDH1A1ALOX12KDM4ERAB9A | |
| SCHEMBL6957779 | 0.85 | STK17B (0.49) | ALOX12SMN1; SMN2HTTCYP3A4TDP1 | |
| SCHEMBL13592325 | 0.85 | POLB (0.52) | POLBALDH1A1ALOX12KDM4ERAB9A | |
| SCHEMBL29263638 | 0.84 | TDP1 (0.51) | ALOX12SMN1; SMN2HTTNPSR1CYP3A4 | |
| SCHEMBL6300342 | 0.83 | STK17B (0.52) | ALOX12KDM4ESMN1; SMN2HTTCYP3A4 | |
| SCHEMBL3146288 | 0.81 | GAA (0.54) | POLBALDH1A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL4396662 | 0.81 | KMT2A (0.54) | POLBALDH1A1ALOX12RAB9ASMN1; SMN2 | |
| SCHEMBL5739547 | 0.81 | ALDH1A1 (0.66) | POLBALDH1A1ALOX12KDM4ERAB9A | |
| SCHEMBL1258720 | 0.80 | ALDH1A1 (0.53) | POLBALDH1A1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4399373 | 0.80 | RAB9A (0.54) | ALDH1A1RAB9ASMN1; SMN2LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1300401-B1 | THIAZOLE DERIVATIVES FOR USE AS ANTIINFLAMMATORIES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7396842-B2 | Five-membered cyclic compounds | DIANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396842-B2 | Five-membered cyclic compounds | DIANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20050222226-A1 | Five-membered cyclic compounds | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2005-10-06 | — | — | US | disclosed |
| US-6919361-B2 | Five-membered-ring compound | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040072827-A1 | Five-membered-ring compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1300401-A1 | FIVE-MEMBERED-RING COMPOUND | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072827-A1 | Five-membered-ring compound | EPX, IL5, CCR9 | POLB 2950/4885ALDH1A1 3257/4885ALOX12 237/4885 |
| US-20050222226-A1 | Five-membered cyclic compounds | EPX, CCL11, CCR9 | POLB 2695/4885ALDH1A1 3404/4885ALOX12 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.